Lead Inventor: Howard Lieberman, Ph.D.
Mouse with tumor marker Rad9 protein in the prostate as model for prostate cancer:
Prostate cancer is the second leading cause of cancer death in men. Although various therapeutic modalities exist currently (surgical, anti-hormone therapy, etc.) for prostate cancer, malignant and aggressive types of this disease remain refractory to current standard practices. Indeed, current research and development has focused on the formulation of new classes of drugs/compounds that may help improve survival. Animal models of prostate cancer are essential and needed for pre-clinical screening of these novel drugs potentially useful as therapeutic agents.
Mouse model of prostate cancer predisposed to prostate carcinogenesis:
This technology is the construction of a mouse model of prostate cancer which is genetically predisposed to prostate carcinogenesis. The model is based upon aberrant overproduction of the Rad9 protein in the prostate, a known established tumor marker that is present at high levels in human prostate cancer specimens. Animals from this mouse line develop prostate cancer representing different stages of the disease, and are an ideal tool for testing the efficacy of novel anti-cancer compounds or procedures.
Applications:
• Drug development screening of novel anti-prostate cancer compounds
• Screening development of novel therapeutic procedures for prostate cancer, such as radiation therapy
Advantages:
• Novel animal model
• Murine line allows easy further genetic manipulation for custom purposes
Patent Status: Copyright / Animals available for fee
Licensing Status: Available for Licensing and Sponsored Research Support
Publications: Zhu A, Zhang CX and Lieberman HB. Rad9 has a functional role in human prostate carcinogenesis. Cancer Res. 68:1267-74, (2008)
